The estimated Net Worth of James C Hamilton is at least $12.4 Million dollars as of 1 April 2024. Dr Hamilton owns over 6,000 units of Arrowhead Pharmaceuticals stock worth over $4,289,580 and over the last 4 years he sold ARWR stock worth over $8,091,538.
Dr has made over 9 trades of the Arrowhead Pharmaceuticals stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 6,000 units of ARWR stock worth $168,180 on 1 April 2024.
The largest trade he's ever made was selling 38,750 units of Arrowhead Pharmaceuticals stock on 5 January 2021 worth over $2,809,763. On average, Dr trades about 13,991 units every 107 days since 2021. As of 1 April 2024 he still owns at least 204,851 units of Arrowhead Pharmaceuticals stock.
You can see the complete history of Dr Hamilton stock trades at the bottom of the page.
Dr. James C. Hamilton is the Sr. VP of Discovery & Translational Medicine at Arrowhead Pharmaceuticals.
Dr Hamilton is 43, he's been the Sr. VP of Discovery & Translational Medicine of Arrowhead Pharmaceuticals since . There are 17 older and no younger executives at Arrowhead Pharmaceuticals. The oldest executive at Arrowhead Pharmaceuticals Inc. is Dr. Mark Seefeld, 67, who is the Head of Toxicology & VP.
James's mailing address filed with the SEC is 177 EAST COLORADO BLVD, SUITE 700, PASADENA, CA, 91105.
Over the last 21 years, insiders at Arrowhead Pharmaceuticals have traded over $129,489,075 worth of Arrowhead Pharmaceuticals stock and bought 176,205 units worth $991,784 . The most active insiders traders include David M Knott, Christopher Richard Anzalone, and Kenneth Allen Myszkowski. On average, Arrowhead Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of $868,068. The most recent stock trade was executed by Tracie Oliver on 2 July 2024, trading 9,394 units of ARWR stock currently worth $237,480.
arrowhead pharmaceuticals is a clinical stage, nasdaq listed (ticker arwr) company developing medicines that treat intractable diseases by silencing the genes that cause them. using a broad portfolio of rna chemistries and efficient modes of delivery, our therapies trigger the rna interference mechanism to induce rapid, deep and durable knockdown of target genes. rna interference, or rnai, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. our rnai-based therapeutics are at the leading edge of genetic-based therapy with the potential to bring life changing treatments for patients. our targeted rnai molecule (trimtm) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. the trim platform builds on more than a decade of work on actively targeted drug delivery and offers several advantages including simplified manufacturing
Arrowhead Pharmaceuticals executives and other stock owners filed with the SEC include: